Literature DB >> 32304670

Check and Checkmate: Battling Cancer with Multiplex Immunotherapy.

John C Bell1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32304670      PMCID： PMC7210718          DOI： 10.1016/j.ymthe.2020.04.013

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  16 in total

1.  Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss.

Authors:  Ali Bukhari; Firas El Chaer; Rima Koka; Zeba Singh; Elizabeth Hutnick; Kathleen Ruehle; Seung Tae Lee; Mehmet H Kocoglu; Carl Shanholtz; Ashraf Badros; Nancy Hardy; Jean Yared; Aaron P Rapoport; Saurabh Dahiya
Journal:  Am J Hematol       Date:  2019-08-13       Impact factor: 10.047

Review 2.  Recent advances in oncolytic virus-based cancer therapy.

Authors:  Luo-Qin Fu; Shi-Bing Wang; Mao-Hua Cai; Xue-Jun Wang; Jin-Yang Chen; Xiang-Min Tong; Xiao-Yi Chen; Xiao-Zhou Mou
Journal:  Virus Res       Date:  2019-07-25       Impact factor: 3.303

Review 3.  Elements of cancer immunity and the cancer-immune set point.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Nature       Date:  2017-01-18       Impact factor: 49.962

Review 4.  Oncology meets immunology: the cancer-immunity cycle.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

5.  Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.

Authors:  Caroline E Porter; Amanda Rosewell Shaw; Youngrock Jung; Tiffany Yip; Patricia D Castro; Vlad C Sandulache; Andrew Sikora; Stephen Gottschalk; Michael M Ittman; Malcolm K Brenner; Masataka Suzuki
Journal:  Mol Ther       Date:  2020-02-24       Impact factor: 11.454

Review 6.  Synergistic combination of oncolytic virotherapy with CAR T-cell therapy.

Authors:  Adam Ajina; John Maher
Journal:  Prog Mol Biol Transl Sci       Date:  2019-07-19       Impact factor: 3.622

7.  Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.

Authors:  Elena J Orlando; Xia Han; Catherine Tribouley; Patricia A Wood; Rebecca J Leary; Markus Riester; John E Levine; Muna Qayed; Stephan A Grupp; Michael Boyer; Barbara De Moerloose; Eneida R Nemecek; Henrique Bittencourt; Hidefumi Hiramatsu; Jochen Buechner; Stella M Davies; Michael R Verneris; Kevin Nguyen; Jennifer L Brogdon; Hans Bitter; Michael Morrissey; Piotr Pierog; Serafino Pantano; Jeffrey A Engelman; Wendy Winckler
Journal:  Nat Med       Date:  2018-10-01       Impact factor: 53.440

8.  First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial.

Authors:  Keri A Streby; Mark A Currier; Melinda Triplet; Kristy Ott; Devon J Dishman; Michele R Vaughan; Mark A Ranalli; Bhuvana Setty; Micah A Skeens; Stacy Whiteside; Nicholas D Yeager; Kellie B Haworth; Kathleen Simpson; Joe Conner; Timothy P Cripe
Journal:  Mol Ther       Date:  2019-09-10       Impact factor: 11.454

9.  Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy.

Authors:  Lisa Farzad; Vincenzo Cerullo; Shigeki Yagyu; Terry Bertin; Akseli Hemminki; Cliona Rooney; Brendan Lee; Masataka Suzuki
Journal:  Mol Ther Oncolytics       Date:  2014-12-17       Impact factor: 7.200

Review 10.  Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment.

Authors:  Amanda Rosewell Shaw; Masataka Suzuki
Journal:  Front Immunol       Date:  2018-09-21       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.